Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.82%||165.21||0.7%||$952.05m|
|MRK||Merck & Co., Inc.||-0.69%||80.73||0.7%||$844.40m|
|BMY||Bristol-Myers Squibb Co.||-0.17%||64.61||1.0%||$686.91m|
|LLY||Eli Lilly & Co.||-0.76%||243.20||1.1%||$618.39m|
|NVO||Novo Nordisk A/S||-1.86%||95.48||0.1%||$149.54m|
|IMMX||Immix Biopharma, Inc.||-4.24%||5.42||0.0%||$85.35m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||0.87%||116.04||0.0%||$75.90m|
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firmâ€™s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on August 4, 2009 and is headquartered in Pittsburgh, PA.